Advanced search
Publication Cover
Blood Pressure Volume 21, 2012 - Issue 1
Submit an article Journal homepage
177
Views
0
CrossRef citations to date
0
Altmetric
EDITORIAL

Increased time varying heart rate and cardiovascular risk in hypertension – Benefit of selective I(f) channel inhibitor?

Sverre E. KjeldsenDept of Cardiology (SEK), University of Oslo, Ullevaal Hospital, Oslo Norway
,
Thomas HednerDept of Medicine (TH), University of Göteborg, Sahlgrenska Academy, Göteborg Sweden
,
Krzysztof NarkiewiczDept of Hypertension and Diabetology (KN), Medical University of Gdansk, Poland
&
Suzanne OparilVascular Biology and Hypertension Program (SO), University of Alabama, Birmingham, Alabama, USA
Pages 1-2 | Published online: 23 Jan 2012

References

  • Levy RL, White PD, Stroud WD . Transient tachycardia: prognostic significance alone and in association with transient hypertension. JAMA. 1945;129:585–588.
  • Dyer A, Persky V, Stamler J . Heart rate as a prognostic factor for coronary heart disease and mortality findings in three Chicago epidemiological studies. Am J Epidemiol. 1980;112:736–749.
  • Kannel WB, Kannel C, Paffenbarger RS Jr . Heart rate and cardiovascular mortality: The Framingham Study. Am Heart J. 1987;113:1489–1494.
  • Gillum RF, Makuc DM, Feldman JJ. Pulse rate, coronary heart disease, and death: The NHANES I epidemiologic follow-up study. Am Heart J. 1991;121:172–177.
  • Benetos A, Rudnichi A, Thomas F . Influence of heart rate on mortality in a French population: role of age, gender and blood pressure. Hypertension. 1999;33:44–52.
  • Julius S, Jamerson K, Mejia A . The association of borderline hypertension with target organ changes and higher coronary risk. Tecumseh Blood Pressure Study. JAMA. 1990; 264:354–358.
  • Selby JV, Friedman GD, Quesensberry P. Precursor of essential hypertension: Pulmonary function, heart rate, uric acid, serum cholesterol and other serum chemistries. Am J Epidemiol. 1990;131:1017–1027.
  • Messerli FH, Frolich ED, Suarez DH . Borderline hypertension: Relationship between age hemodynamics and circulating catecholamines. Circulation. 1981;64:760–764.
  • Kjeldsen SE, Schork NJ, Leren P . Arterial plasma norepinephrine correlates to blood pressure in middle-aged men with sustained essential hypertension. Am Heart J. 1989;118: 775–781.
  • Tjugen T, Flaa A, Kjeldsen SE. Increased heart rate as a predictor of hypertension. Progress Cardiovasc Dis. 2009; 52:20–25.
  • Okin PM, Kjeldsen SE, Julius S . Effect of changing heart rate during treatment of hypertension on incidence of heart failure. Am J Cardiol. doi:10.1016/j.amjcard.2011.10.026.
  • Julius S, Palatini P, Kjeldsen SE . Heart rate predicts cardiac events in treated high risk hypertension. Am J Cardiol doi:10.1016/j.amjcard.2011.10.025.
  • Okin PM, Kjeldsen SE, Julius S . All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. Eur Heart J. 2010; 31:2271–2279.
  • Okin PM, Wachtell K, Kjeldsen SE . Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE Study. Circ Arrhythmia Electrophysiol. 2008;1:337–343.
  • Fox K, Ford I, Tendera M, Ferrari R on behalf of the BEAUTIFUL investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807–816.
  • Böhm M, Swedberg K, Komajda M . on behalf of the SHIFT Investigators. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010;376:886–894.
  • Swedberg K, Komajda M, Böhm M . on behalf of the SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875–885.
  • Palatini P, Benetos A, Grassi G . Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J Hypertens. 2006,24:603–610.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.